Fig. 3: Longitudinal evolution of genomic alterations including MET amplification and resistance mutation. | npj Precision Oncology

Fig. 3: Longitudinal evolution of genomic alterations including MET amplification and resistance mutation.

From: Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

Fig. 3

A Representative fluorescence in situ hybridization (FISH) images for ROS1 rearrangement (top), EGFR copy number relative to CEP7, and MET copy number relative to CEP7 (bottom). Split signals (white lines) denote ROS1 rearrangement. B The EGFR-to-CEP7 ratio (i.e., the ratio of the green signals to the white signals) and MET-to-CEP7 ratio (i.e., the ratio of the red signals to the white signals) are shown at the indicated time points throughout the disease course. C Guardant360 cell-free DNA (cfDNA) response map showing dynamic changes in variant allele fractions of gene alterations. The evolution of variant alleles over time, represented as % cfDNA, is depicted (bottom). Timepoint 0 = plasma liquid biopsy prior to starting lorlatinib treatment.

Back to article page